C. Sessa

693 total citations
26 papers, 447 citations indexed

About

C. Sessa is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C. Sessa has authored 26 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C. Sessa's work include Ovarian cancer diagnosis and treatment (5 papers), Cancer Treatment and Pharmacology (5 papers) and Lung Cancer Treatments and Mutations (5 papers). C. Sessa is often cited by papers focused on Ovarian cancer diagnosis and treatment (5 papers), Cancer Treatment and Pharmacology (5 papers) and Lung Cancer Treatments and Mutations (5 papers). C. Sessa collaborates with scholars based in Switzerland, Italy and United States. C. Sessa's co-authors include N. Colombo, Jonathan A. Ledermann, F. Raja, Antonio González-Martı́n, Christina Fotopoulou, Matti Aapro, Rudolf Maibach, Jürg Bernhard, C. Mangioni and G. Catimel and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

C. Sessa

25 papers receiving 433 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Sessa Switzerland 10 203 122 106 105 91 26 447
V. Barley United Kingdom 9 120 0.6× 42 0.3× 131 1.2× 183 1.7× 97 1.1× 15 453
Rocco De Vivo Italy 14 166 0.8× 78 0.6× 109 1.0× 96 0.9× 172 1.9× 27 429
Jean Pierre Lotz France 10 366 1.8× 115 0.9× 101 1.0× 69 0.7× 127 1.4× 21 566
M. Beer United States 15 266 1.3× 111 0.9× 175 1.7× 16 0.2× 99 1.1× 33 555
O. Dalesio Netherlands 12 312 1.5× 79 0.6× 237 2.2× 33 0.3× 325 3.6× 25 607
Roberto Valenza Italy 13 296 1.5× 40 0.3× 122 1.2× 15 0.1× 159 1.7× 41 477
László Thurzó Hungary 14 213 1.0× 110 0.9× 82 0.8× 26 0.2× 131 1.4× 45 613
D A Hall United States 16 110 0.5× 100 0.8× 164 1.5× 174 1.7× 141 1.5× 23 671
W. Mattsson Sweden 15 271 1.3× 73 0.6× 74 0.7× 32 0.3× 75 0.8× 29 474
Jane E. Latz United States 14 391 1.9× 131 1.1× 51 0.5× 21 0.2× 447 4.9× 28 664

Countries citing papers authored by C. Sessa

Since Specialization
Citations

This map shows the geographic impact of C. Sessa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Sessa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Sessa more than expected).

Fields of papers citing papers by C. Sessa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Sessa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Sessa. The network helps show where C. Sessa may publish in the future.

Co-authorship network of co-authors of C. Sessa

This figure shows the co-authorship network connecting the top 25 collaborators of C. Sessa. A scholar is included among the top collaborators of C. Sessa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Sessa. C. Sessa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ponce, Santiago, Emiliano Calvo, Maria J. de Miguel, et al.. (2019). P2.12-13 Lurbinectedin (L) Combined with Paclitaxel (P) or Irinotecan (I) in Relapsed SCLC. Results from Two Phase Lb Trials. Journal of Thoracic Oncology. 14(10). S817–S817. 3 indexed citations
3.
Drilon, Alexander, Elena Garralda, Anastasios Stathis, et al.. (2016). Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion results with or without the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors. Annals of Oncology. 27. vi125–vi125. 4 indexed citations
4.
5.
Conte, Gianluca Del, et al.. (2008). Results from a phase 1/2 study of volociximab in combination with liposomal doxorubicin in relapsed advanced epithelial ovarian and primary peritoneal carcinoma. Journal of Clinical Oncology. 26(15_suppl). 16527–16527. 8 indexed citations
6.
Boni, C., Teresa Gamucci, Andrea Bonetti, et al.. (2004). A phase II study of the novel oral camptothecin ST1481 in pretreated metastatic colorectal cancer (CRC). Journal of Clinical Oncology. 22(14_suppl). 3684–3684. 4 indexed citations
7.
Boni, C., Teresa Gamucci, Andrea Bonetti, et al.. (2004). A phase II study of the novel oral camptothecin ST1481 in pretreated metastatic colorectal cancer (CRC). Journal of Clinical Oncology. 22(14_suppl). 3684–3684. 3 indexed citations
8.
9.
Bernhard, Jürg, Rudolf Maibach, Beat Thürlimann, C. Sessa, & Matti Aapro. (2002). Patients’ Estimation of Overall Treatment Burden: Why Not Ask the Obvious?. Journal of Clinical Oncology. 20(1). 65–72. 26 indexed citations
10.
Roth, A, Nicola Fazio, Olivia Pagani, et al.. (1999). 5FU as protracted continuous IV infusion (5FUpiv) can be added to full dose taxotere-cisplatin (TC) in advanced gastric carcinoma (AGC). European Journal of Cancer. 35. S139–S139. 8 indexed citations
11.
Buser, K., M. Bacchi, Aron Goldhirsch, et al.. (1996). Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation. Annals of Oncology. 7(1). 65–70. 12 indexed citations
12.
Catimel, G., Jan B. Vermorken, M. Clavel, et al.. (1994). A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Annals of Oncology. 5(6). 543–547. 108 indexed citations
13.
Rajnoldi, A. Cantù, Valentino Conter, Giuseppe Masera, et al.. (1993). Childhood acute promyelocytic leukemia in Nicaragua. Annals of Oncology. 4(10). 892–894. 25 indexed citations
14.
Thigpen, J.T., K. Bertelsen, E. Eisenhauer, et al.. (1993). Long-term follow-up of patients with advanced ovarian carcinoma treated with chemotherapy. Annals of Oncology. 4. S35–S40. 21 indexed citations
15.
Cattaneo, María Teresa, C. Sessa, Emanuele Zucca, et al.. (1987). Enzymuria in Carboplatin Nephrotoxicity. Tumori Journal. 73(5). 487–491. 2 indexed citations
16.
Kaplan, Steven, et al.. (1985). Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer.. PubMed. 69(11). 1337–8. 4 indexed citations
17.
Sessa, C., et al.. (1982). [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma].. PubMed. 112(26). 930–3. 2 indexed citations
18.
D’Incalci, Maurizio, C. Sessa, Gino Beggiolin, & C. Mangioni. (1981). Cerebrospinal fluid levels of hexamethylmelamine and N-demethylated metabolites.. PubMed. 65(3-4). 350–1. 6 indexed citations
19.
D’Incalci, Maurizio, Gino Beggiolin, C. Sessa, & C. Mangioni. (1981). Influence of ascites on the pharmacokinetics of hexamethylmelamine andN-demethylated metabolites in ovarian cancer patients. European Journal of Cancer and Clinical Oncology. 17(12). 1331–1335. 16 indexed citations
20.
D’Incalci, Maurizio, C. Sessa, & C Belloni. (1979). Hexamethylmelamine (HMM) and pentamethylmelamine (PMM) levels in plasma and ascites after oral administration to ovarian cancer patients. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by V. Barley Breakdown of academic impact, for papers by Rocco De Vivo Breakdown of academic impact, for papers by Jean Pierre Lotz Breakdown of academic impact, for papers by M. Beer Breakdown of academic impact, for papers by O. Dalesio Breakdown of academic impact, for papers by Roberto Valenza Breakdown of academic impact, for papers by László Thurzó Breakdown of academic impact, for papers by D A Hall Breakdown of academic impact, for papers by W. Mattsson Breakdown of academic impact, for papers by Jane E. Latz
Rankless by CCL
2026